Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[e]isoindole α1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)

Journal of Medicinal Chemistry
2000.0

Abstract

In search of a uroselective agent that exhibits a high level of selectivity for the alpha(1A) receptor, a novel series of tricyclic hexahydrobenz[e]isoindoles was synthesized. A generic pharmacophoric model was developed requiring the presence of a basic amine core and a fused heterocyclic side chain separated by an alkyl chain. It was shown that the 6-OMe substitution with R, R stereochemistry of the ring junction of the benz[e]isoindole and a two-carbon spacer chain were optimal. In contrast to the highly specific requirements for the benz[e]isoindole portion and linker chain, a wide variety of tricyclic fused heterocyclic attachments were tolerated with retention of potency and selectivity. In vitro functional assays for the alpha(1) adrenoceptor subtypes were used to further characterize these compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity.

Knowledge Graph

Similar Paper

Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[e]isoindole α<sub>1A</sub> Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
Journal of Medicinal Chemistry 2000.0
Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[e]isoindole α<sub>1A</sub> Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia
Journal of Medicinal Chemistry 2001.0
Synthesis and Pharmacological Characterization of 3-[2-((3aR,9bR)-cis-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1H- benz[e]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-d]pyrimidine- 2,4(1H,3H)-dione (A-131701):  A Uroselective α<sub>1A</sub> Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia
Journal of Medicinal Chemistry 1997.0
(Phenylpiperazinyl)cyclohexylureas: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)
Bioorganic &amp; Medicinal Chemistry Letters 2008.0
(Phenylpiperidinyl)cyclohexylsulfonamides: Development of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)
Bioorganic &amp; Medicinal Chemistry Letters 2007.0
(Arylpiperazinyl)cyclohexylsufonamides: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS)
Bioorganic &amp; Medicinal Chemistry Letters 2007.0
Design and Synthesis of Novel α<sub>1a</sub> Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia
Journal of Medicinal Chemistry 1998.0
Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues
European Journal of Medicinal Chemistry 2010.0
Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α<sub>1A</sub>-Adrenoceptor Antagonists
Journal of Medicinal Chemistry 2016.0
Design and synthesis of selective α1B adrenoceptor antagonists
Bioorganic &amp; Medicinal Chemistry Letters 2006.0